Antagonists of the brandykinin B1 receptor
AssigneeAmgen Inc.
InventorsGordon Ng, Benny C. Askew, Jr., Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu
Life of this patent
Estimating the term…
Abstract
The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugated peptides are provided. In one aspect of the present invention, pharmacologically active PEG-conjugated peptides of the present invention are useful to treat inflammation or pain.
Claims11
A peptide antagonist of the bradykinin B1 receptor comprising a sequence of amino acids selected from the group consisting of SEQ ID NOS:
- 15-18, 23, 25, 26, 39, 41, 45, 44, and 46-51, or a physiologically acceptable salt thereof.
A peptide antagonist of the bradykinin B1 receptor comprising a sequence of amino acids selected from the group consisting of SEQ ID NOS:
- 15-18, 23, 25, and 26, or a physiologically acceptable salt thereof.
A pharmaceutical composition comprising a peptide antagonist of the bradykinin B1 receptor comprising a sequence of amino acids selected from the group consisting of SEQ ID NOS:
- 15-18, 23, 25, and 26;
- and at least one pharmaceutically-acceptable diluent, excipient, or carrier.
Dependencies are inferred from the claim text.